These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747 [TBL] [Abstract][Full Text] [Related]
8. Gallium-68-prostate-specific membrane antigen ( van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667 [TBL] [Abstract][Full Text] [Related]
9. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values. Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016 [TBL] [Abstract][Full Text] [Related]
10. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071 [TBL] [Abstract][Full Text] [Related]
11. A Prospective Study on [ Harsini S; Fallahi B; Karamzade Ziarati N; Razi A; Amini E; Emami-Ardekani A; Fard-Esfahani A; Kardoust Parizi M; Farzanehfar S; Beiki D Asia Ocean J Nucl Med Biol; 2021; 9(2):101-110. PubMed ID: 34250139 [TBL] [Abstract][Full Text] [Related]
13. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre. Haran C; McBean R; Parsons R; Wong D J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933 [TBL] [Abstract][Full Text] [Related]
14. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316 [TBL] [Abstract][Full Text] [Related]
15. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience. Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365 [TBL] [Abstract][Full Text] [Related]
16. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731 [TBL] [Abstract][Full Text] [Related]
17. Correlations of Topuz ÖV; Aksu A; Erinç SR; Tamam MÖ Hell J Nucl Med; 2021; 24(1):60-65. PubMed ID: 33866340 [TBL] [Abstract][Full Text] [Related]
18. Impact of uptake time on image quality of [ van der Sar ECA; Viol SLM; Braat AJAT; van Rooij R; Lam MGEH; de Jong HWAM; de Keizer B Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883 [TBL] [Abstract][Full Text] [Related]
19. Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038 [TBL] [Abstract][Full Text] [Related]